Skip to main content
. 2012 Apr 13;3(3):345–356. doi: 10.18632/oncotarget.457

Figure 1. GW9662 enhances the sensitivity of mammary tumors to fulvestrant.

Figure 1

(A) Survival curves of mice administered a control diet, a diet supplemented with 0.1% (w/w) GW9662, 250 mg/kg fulvestrant administered s.c. every other week or the combination of the GW9662 diet and fulvestrant. GW9662 treatment alone produced a significant reduction in survival vs. control mice (P=0.0382), but not vs. fulvestrant treatment (P=0.0759); fulvestrant treatment alone did not significantly affect survival (P=0.7223). GW9662 and fulvestrant treatment produced a significant increase in survival vs. fulvestrant (P=0.0008) or GW9662 (P=0.0001) treatment alone. Each group contained 10 mice. Statistical significance was determined by the log rank test. (B) Tumor formation in the experimental groups indicated in (A). Neither GW9662 (P=0.3942) nor fulvestrant (P=0.3339) treatment alone significantly affected tumor number vs. control mice. GW9662 and fulvestrant treatment produced a significant reduction in tumor number vs. either fulvestrant (P=0.0001) or GW9662 (P=0.0004) treatment alone. Each group contained 10 mice. Statistical significance was determined by the two-tailed Student's t test.